Silvan Tuerkcan
Stock Analyst
(n/a)
# 4,648
Out of 4,648 analysts
129
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Silvan Tuerkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Maintains: Market Outperform | $29 → $34 | $34.12 | -0.35% | 17 | Oct 16, 2024 | |
| JSPR Jasper Therapeutics | Reiterates: Market Outperform | $70 | $21.27 | +229.10% | 3 | Oct 15, 2024 | |
| BNTC Benitec Biopharma | Maintains: Market Outperform | $16 → $18 | $10.92 | +64.84% | 9 | Oct 14, 2024 | |
| RLAY Relay Therapeutics | Reiterates: Market Outperform | $21 | $5.84 | +259.59% | 9 | Sep 17, 2024 | |
| ACRV Acrivon Therapeutics | Reiterates: Market Outperform | $17 | $8.01 | +112.23% | 4 | Sep 16, 2024 | |
| TERN Terns Pharmaceuticals | Maintains: Market Outperform | $15 → $20 | $6.94 | +188.18% | 10 | Sep 10, 2024 | |
| VOR Vor Biopharma | Reiterates: Market Outperform | $12 | $0.80 | +1,391.05% | 10 | Sep 6, 2024 | |
| MGNX MacroGenics | Maintains: Market Outperform | $16 → $8 | $3.87 | +106.72% | 11 | Jul 31, 2024 | |
| ELEV Elevation Oncology | Reiterates: Market Outperform | $7 | $0.54 | +1,205.97% | 4 | Jul 15, 2024 | |
| TSHA Taysha Gene Therapies | Reiterates: Market Outperform | $5 | $1.53 | +226.80% | 10 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $1.80 | +233.33% | 6 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $86 | $50.76 | +69.42% | 12 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $280 | $299.55 | -6.53% | 3 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.21 | - | 7 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $18 → $18 | $11.40 | +57.89% | 1 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $14.81 | - | 10 | Jan 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $2 → $3 | $6.38 | -52.98% | 3 | May 10, 2022 |
Exelixis
Oct 16, 2024
Maintains: Market Outperform
Price Target: $29 → $34
Current: $34.12
Upside: -0.35%
Jasper Therapeutics
Oct 15, 2024
Reiterates: Market Outperform
Price Target: $70
Current: $21.27
Upside: +229.10%
Benitec Biopharma
Oct 14, 2024
Maintains: Market Outperform
Price Target: $16 → $18
Current: $10.92
Upside: +64.84%
Relay Therapeutics
Sep 17, 2024
Reiterates: Market Outperform
Price Target: $21
Current: $5.84
Upside: +259.59%
Acrivon Therapeutics
Sep 16, 2024
Reiterates: Market Outperform
Price Target: $17
Current: $8.01
Upside: +112.23%
Terns Pharmaceuticals
Sep 10, 2024
Maintains: Market Outperform
Price Target: $15 → $20
Current: $6.94
Upside: +188.18%
Vor Biopharma
Sep 6, 2024
Reiterates: Market Outperform
Price Target: $12
Current: $0.80
Upside: +1,391.05%
MacroGenics
Jul 31, 2024
Maintains: Market Outperform
Price Target: $16 → $8
Current: $3.87
Upside: +106.72%
Elevation Oncology
Jul 15, 2024
Reiterates: Market Outperform
Price Target: $7
Current: $0.54
Upside: +1,205.97%
Taysha Gene Therapies
Jun 20, 2024
Reiterates: Market Outperform
Price Target: $5
Current: $1.53
Upside: +226.80%
May 31, 2024
Reiterates: Market Outperform
Price Target: $6
Current: $1.80
Upside: +233.33%
May 9, 2024
Reiterates: Market Outperform
Price Target: $86
Current: $50.76
Upside: +69.42%
Mar 5, 2024
Maintains: Buy
Price Target: $240 → $280
Current: $299.55
Upside: -6.53%
Oct 23, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $2.21
Upside: -
Jan 26, 2023
Maintains: Market Outperform
Price Target: $18 → $18
Current: $11.40
Upside: +57.89%
Jan 19, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $14.81
Upside: -
May 10, 2022
Maintains: Market Outperform
Price Target: $2 → $3
Current: $6.38
Upside: -52.98%